Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Status:
Terminated
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The MEDiaN study aims to examine the state of fuel metabolism in participants with diabetic
nephropathy (DN) before and after the use of the sodium-glucose transport protein 2 inhibitor
(SGLT-2i) empagliflozin. The goals of the MEDiaN study are to better understand the
contribution of fuel metabolism to the development of DN, and to determine if changes to fuel
metabolism can have a positive impact on this disease.
The MEDiaN study is a single-center single-arm open-label intervention study to examine the
effects of empagliflozin 10mg daily taken for 30 days on fuel oxidation patterns in
participants with type 2 diabetes and DN.